Dennis Ding
Stock Analyst at Jefferies
(2.18)
# 2,861
Out of 5,132 analysts
15
Total ratings
40%
Success rate
12.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dennis Ding
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FOLD Amicus Therapeutics | Downgrades: Hold | $16 → $15 | $14.31 | +1.33% | 2 | Jan 22, 2026 | |
| ROIV Roivant Sciences | Maintains: Buy | $18 → $20 | $26.45 | -24.39% | 2 | Sep 18, 2025 | |
| MLYS Mineralys Therapeutics | Maintains: Hold | $15 → $26 | $27.60 | -5.80% | 2 | Sep 3, 2025 | |
| CRNX Crinetics Pharmaceuticals | Upgrades: Buy | $55 | $42.67 | +28.90% | 1 | Jan 22, 2025 | |
| IKT Inhibikase Therapeutics | Initiates: Buy | $8 | $1.67 | +379.04% | 1 | Nov 8, 2024 | |
| ASMB Assembly Biosciences | Upgrades: Buy | $2 → $35 | $26.66 | +31.28% | 1 | Sep 20, 2024 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 → $7 | $3.98 | +75.88% | 2 | Sep 5, 2024 | |
| RXRX Recursion Pharmaceuticals | Maintains: Hold | $8 → $6 | $3.49 | +71.92% | 1 | Sep 3, 2024 | |
| LYRA Lyra Therapeutics | Downgrades: Hold | $500 → $25 | $1.39 | +1,698.56% | 1 | May 7, 2024 | |
| CORT Corcept Therapeutics | Downgrades: Hold | $35 → $22 | $39.97 | -44.96% | 1 | Feb 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $34.63 | -30.70% | 1 | Dec 19, 2022 |
Amicus Therapeutics
Jan 22, 2026
Downgrades: Hold
Price Target: $16 → $15
Current: $14.31
Upside: +1.33%
Roivant Sciences
Sep 18, 2025
Maintains: Buy
Price Target: $18 → $20
Current: $26.45
Upside: -24.39%
Mineralys Therapeutics
Sep 3, 2025
Maintains: Hold
Price Target: $15 → $26
Current: $27.60
Upside: -5.80%
Crinetics Pharmaceuticals
Jan 22, 2025
Upgrades: Buy
Price Target: $55
Current: $42.67
Upside: +28.90%
Inhibikase Therapeutics
Nov 8, 2024
Initiates: Buy
Price Target: $8
Current: $1.67
Upside: +379.04%
Assembly Biosciences
Sep 20, 2024
Upgrades: Buy
Price Target: $2 → $35
Current: $26.66
Upside: +31.28%
Arbutus Biopharma
Sep 5, 2024
Maintains: Buy
Price Target: $5 → $7
Current: $3.98
Upside: +75.88%
Recursion Pharmaceuticals
Sep 3, 2024
Maintains: Hold
Price Target: $8 → $6
Current: $3.49
Upside: +71.92%
Lyra Therapeutics
May 7, 2024
Downgrades: Hold
Price Target: $500 → $25
Current: $1.39
Upside: +1,698.56%
Corcept Therapeutics
Feb 15, 2023
Downgrades: Hold
Price Target: $35 → $22
Current: $39.97
Upside: -44.96%
Dec 19, 2022
Initiates: Buy
Price Target: $24
Current: $34.63
Upside: -30.70%